EMEA-002961-PIP01-21-M01
Key facts
| Invented name |
Regkirona
|
| Active substance |
Regdanvimab
|
| Therapeutic area |
Vaccines
|
| Decision number |
P/0166/2022
|
| PIP number |
EMEA-002961-PIP01-21-M01
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of Coronavirus disease 2019 (COVID-19)
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Celltrion Healthcare Hungary Kft.
Email: regulatory_eu@celltrion.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|